



Press Release
Stockholm, Sweden – May 17, 2004

FDA clears DXL Calscan – 1st of new generation bone densitometers

Stockholm, Sweden – May 17, 2004 - Demetech AB announced the US FDA has cleared the company's DXL Calscan bone densitometer for market and sale in the United States. DXL Calscan is the first device to use Demetech's patented DXA + Laser measurement technique (DXL), enabling extremely high accuracy in measurement results.

"While DXA technology is widely accepted as the densitometry standard today, it still assumes a constant relationship between lean soft tissue and adipose tissue (fat). This generalization results in significant errors in some patient measurements. DXL technology has the ability to more accurately separate both these soft tissues from bone and therefore improve accuracy. DXL is a welcome advancement for better accuracy in densitometry." according to Claus C. Glüer, Prof. Med. Physics, Kiel University, Germany, and a leading international expert & lecturer on bone densitometry.

DXL technology estimates bone mineral density (BMD), using the conventional dual energy x-ray absorptiometry technique (DXA), but adds laser measurement of the region of interest. Laser measurement enables calculation and exclusion of patient-specific soft adipose tissue (fat) variations from results.

Demetech AB is a Swedish medical device company that develops, manufactures and markets advanced bone density measurement systems. *"FDA clearance of DXL Calscan is an important step for Demetech in North America"*, says Anders Reifeldt, Demetech CEO. The DXL technique represents what Reifeldt calls *"the next generation of x-ray based densitometry"*, and adds, *"We look forward to raising the standard of diagnostic accuracy in a medical device area that has seen too little improvement over the last 10 years"*. A full line of DXL based densitometers is under development.

Osteoporosis is one of the world's largest healthcare problems. With increased longevity, the number of patients with osteoporosis is expected to rise dramatically over the next 20 years. In the USA alone, the direct cost of caring for osteoporotic fractures today is estimated at \$17 billion per year.

Contact: Anders Reifeldt, CEO, Demetech AB
Tel: +46-8-555-79201, anders.reifeldt@demetech.com

John Elliott, Marketing & Information
Tel: +46-8-555-79203, john.elliott@demetech.com

DXL[®] is a registered trademark of Demetech AB in the European Union, the United States and other countries.